ASXL1 and myelodysplastic syndrome: Three MDS patients (two with MDS‐RS‐MLD and one with MDS‐SLD) who were treated with immunomodulatory therapy and erythropoiesis‐stimulating agents (ESAs) did not exhibit clearance of the ASXL1 mutations.